on atheroprotective traits of Omega-3 fatty acids, particularly of eicosapentaenoic acid and docosahexaenoic acid, the precursors of most resolving lipid mediators, namely lipid-lowering effects, and reduced lesional accumulation of macrophages and foam cell numbers. [13] [14] [15] Indeed docosahexaenoic acid, the precursor for RvD1 and RvD2 16, 17 as well as MaR1 8 reduces atherosclerosis in mice, 18 and plasma docosahexaenoic acid levels associate with reduced atheroprogression in coronary arteries in humans. 19 Similarly, 12/15 lipoxygenase, the enzyme responsible for the synthesis of Lipoxin A4, RvD1, and MaR1 was also shown to be protective toward atherosclerosis, 20 setting the stage for the indication that progression of atherosclerosis may be a consequence of failed resolution. 21 Given the associative evidence for atheroprotective effects of the precursors of resolving lipid mediators, and more recently of Resolvin E1 in ApoE*3Leiden mice, 22 we here hypothesized that atheroprogression may partly be explained by an imbalance of the arterial lipid mediator profile. Therefore, we set to investigate how the balance of these mediators changes during the course of atherosclerosis, aiming at identifying relevant resolution-inducing candidates. Our data indicate that arterial levels of MaR1 and RvD2 decrease during atheroprogression and that delivery of these 2 lipid mediators promotes plaque stability.
Methods

Mice
Apoe −/− mice on C57Bl/6 background were fed a high-fat diet (HFD) containing 21% fat (ssniff) for 4 or 8 weeks, 3 months or 4 months as indicated in the respective experimental description. For treatment studies, after 3 months of HFD a combination of MaR1 and RvD2 (each 100 ng, IP, every second day) or vehicle was administered during additional 4 weeks of HFD feeding. The doses for MaR1 and RvD2 were chosen based on previously published studies. 23 All animal experiments were approved by the local ethical committee.
Liquid Chromatography/Tandem Mass Spectrometry
Aortic lipid mediators were measured by liquid chromatography/tandem mass spectrometry as previously described. 24 
Statistics
All data are expressed as mean±SEM. Statistical calculations were performed using GraphPad Prism 5 (GraphPad Software Inc). After calculating for normality by D'Agostino Pearson omnibus test, unpaired Student t test, 1-way ANOVA with Tukey multiple comparison test, Mann-Whitney test, Wilcoxon signed-rank test, and Pearson correlations were used as specified in each figure legend. For detailed Materials and Methods, please see Online Data Supplement.
Results
Atheroprogression Is Characterized by the Imbalance of Inflammatory and Resolving Lipid Mediators
Apoe −/− mice were fed an HFD for 4 weeks, 8 weeks, or 4 months, thus allowing for the development of early 25 and advanced stages of atherosclerosis in mice. 26 To determine lipid mediator levels in atherosclerotic arteries at different stages of atherosclerosis, we subjected snap-frozen aortas from the Apoe −/− mice fed an HFD to liquid chromatography/tandem mass spectrometry analysis (Figure 1 ). At all 3 time points, we detected inflammatory lipid mediators including Prostaglandins (PGE2, PGD2, PGA1, 15d-PGJ2, and 8iso-PGA2) and Leukotriene B4 (LTB4). In addition, we could identify the resolution-inducing lipid mediators RvD2 and MaR1, whereas RvD1, Lipoxin A4, or Protectin Dx were below detection limit. Comparison of the measured lipid mediators during the course of atherosclerosis development showed a significant increase for most of the identified inflammatory lipid mediators with a 4.5-fold increase of LTB4 and a 3-fold increase of PGE2 between the 4 weeks and the 4 months of HFD ( Figure 1A ). In contrast, resolving lipid mediators significantly decreased with prolonged HFD feeding with a 5-fold decrease of RvD2 and a 2.5-fold decrease of MaR1 between the earlier and the later stage of atherosclerosis ( Figure 1B and 1C) . Together, these data indicate that the progression of atherosclerosis in hypercholesterolemic mice is associated with an imbalance between inflammatory and resolving lipid mediators.
Imbalance of Aortic Lipid Mediators Correlates With the Signs of Plaque Stability
To relate aortic lipid mediator signatures to characteristics of atherosclerotic lesions, we assessed signs of lesion stability in aortic root sections in Apoe −/− mice fed an HFD for 4 months and quantified lipid mediators in the aortas of the same mice. Herein, we measured lesion and necrotic core sizes, macrophages and smooth muscle cells, lesional collagen, and fibrous cap thickness. When integrating these parameters into a vulnerability plaque index (VPI), essentially a quotient of destabilizing (macrophages and necrotic core size) and stabilizing (smooth muscle cells and collagen) parameters, an integral impression of plaque stability can be derived. 27 In addition, endothelial activation was assessed by the measurement of ICAM1 (intercellular adhesion molecule 1)-and VCAM1 (vascular cell adhesion molecule 1)-positive endothelial lining.
When correlating lipid mediator levels with the VPI, we found a significant positive correlation for PGE2 and LTB4, whereas the correlation between VPI and RvD2 as well as MaR1 was found to be negative (Online Table I ). No correlation was found for VPI and PGD2, PGA1, 15d-PGJ2, or 8iso-PGA2. When assessing individual plaque characteristics, we observed that PGE2 and LTB4 primarily correlated with lesion size and macrophage accumulation (Figure 2A and 2B; Online Table I ). In stark contrast, RvD2 and MaR1 correlated positively with the number of lesional smooth muscle cells, collagen deposition, and fibrous cap thickness (Figure 2C and 2D; Online Table I ). In addition, RvD2 and MaR1 correlated negatively with necrotic core sizes. Thus, these data suggest that aortic levels of LTB4 and PGE2 associate with 
Administration of RvD2 and MaR1 Prevents Atheroprogression
The decline of both RvD2 and MaR1 during advanced stages of atherosclerosis and the correlation of RvD2 and MaR1 with traits of plaque stability led us to question whether a combined therapeutic delivery of RvD2 and MaR1 would allow arresting plaque progression. Therefore, we subjected hypercholesterolemic Apoe −/− mice to an atheroprogression protocol ( Figure 3A) . Herein, the baseline group was euthanized after 3 months of HFD feeding, time after which treatment was administered to the other 2 groups: a second group that received RvD2 and MaR1 (100 ng each, IP, every second day) during a fourth month of HFD feeding and a third group, treated with vehicle control instead. In mice receiving vehicle control, lesions increased in size and the VPI became progressively worse, a circumstance attributable to an expansion of the necrotic core and the accumulation of macrophages ( Figure 3B through 3I) . In contrast, treatment with RvD2 and MaR1 halted atheroprogression as assessed by VPI. Immunohistomorphologically, treatment with resolving lipid mediators reduced the formation of the necrotic core, decreased plaque macrophage content, and increased the numbers of smooth muscle cells ( Figure 3B through 3I). In line with the latter are the significantly higher levels of total collagen in the group receiving lipid mediators ( Figure 3D ), possibly contributing to a thicker fibrous cap ( Figure 3E) . No difference was observed in endothelial VCAM1 or ICAM1 expression (Online Figure I) . Treatment with RvD2 and MaR1 did also not affect body weight, plasma lipid levels, nor blood cell counts and differential white cell counts in spleen, bone marrow, and lymph nodes (Online Figures II through V) . Taken together, these data indicate that 
RvD2 and MaR1 Dampen Macrophage-Instructed Inflammation
To address the mechanism of halted atheroprogression after MaR1/RvD2 treatment, we first assessed whether the effect was systemic or local. Plasma levels of tumor necrosis factor (TNF), interleukin-6 (IL-6), and IL-13 were not significantly different between the 2 groups, whereas transforming growth factor-β (TGF-β) was enhanced in the MaR1/RvD2-treated group (Online Figure VI) . The latter finding may be supportive of pronounced lesional collagen deposition in these mice. In agreement with nonaltered levels of inflammatory cytokines, the concentration of serum amyloid A, an acute phase protein, was not affected by MaR1/RvD2 administration (Online Figure  VI) . In addition, no changes in phenotypic markers on leukocyte subpopulations in the spleen, the bone marrow, and the blood were found (Online Table II ). Together with unaltered leukocyte counts in blood, bone marrow, and spleen, these data suggest that the observed lesion phenotype does not primarily rely on a systemic but rather a local, lesion-inherent effect.
Therefore, and to better understand the lesional microenvironment, we conducted a whole transcriptome analysis of aortic RNA extracts. After bioinformatic analysis, we identified changes indicative of a macrophage M2 polarization in MaR1/ RvD2-treated mice (Online Figure VII) . To assess macrophage phenotypes in atherosclerotic lesions in more detail, we stained aortic root sections with antibodies to inducible NO synthase and CD206, indicators of an inflammatory M1 or a reparative M2 polarization, respectively. When comparing aortic root section from mice receiving an HFD for 4 weeks with those of 4 months, we evidenceed a clear decrease in the fraction of M2-polarized macrophages with a concomitant increase in M1 macrophage numbers (Online Figure VIII) , thus shifting the balance between these polarization patterns. Comparison of lesions of mice receiving resolving lipid mediators with lesions from vehicle-treated mice then revealed a clear increase of the M2 macrophage fraction on MaR1/RvD2 treatment ( Figure 4A ). This phenotypic switch was further confirmed by quantitative polymerase chain reaction of aortic RNA when quantifying Retnla (also known as Fizz1) and Nos2 ( Figure 4B ). The action of MaR1 and RvD2 on macrophage phenotype was additionally studied in vitro. Herein, macrophages were treated with TNF and interferon-γ to generate a lesion-mimicking macrophage profile. Multiplex cytokine analysis showed that a combination of MaR1 and RvD2 decreased the secretion of TNF and IL-6 by macrophages, whereas increasing that of TGF-β ( Figure 4C ). Gene expression studies confirmed the proresolving effect of these lipid mediators, revealing a decreased expression of Nos2 accompanied by enhanced expression of Arg1 and Tgfb1 ( Figure 4D ) in MaR1/RvD2-treated macrophages.
Because the treatment of atherosclerotic mice with MaR1/ RvD2 affected not only lesional macrophages but also smooth muscle cells and collagen deposition (Figure 3) , we questioned whether the resolving lipid mediators act directly on smooth muscle cells or whether the effect is rather mediated through macrophages. In vitro studies in aortic smooth muscle cells showed that the mRNA expression of genes related to collagen expression and maturation (Col1a1, Col3a1, and P4ha1), as well as inflammation (Vcam1 and Tgfb1) was not directly affected by MaR1/RvD2 treatment ( Figure 4E ). However, when aortic smooth muscle cells were treated with the supernatant of TNF-activated macrophages or of macrophages activated with TNF in the presence of MaR1/RvD2, we observed an increase in mRNA levels of genes involved in collagen production (Col1a1 and Col3a1) in smooth muscle cells receiving the supernatant harvested from reparative macrophages ( Figure 4F) . In line herewith, collagen production was found to be increased in aortic smooth muscle cells after the treatment with the supernatant of reparative macrophages when compared with the treatment with inflammatory macrophages ( Figure 4G ). Interestingly, when blocking TGF-β receptor on smooth muscle cells much of the effect of the supernatant derived from reparative macrophages was lost indicative of the importance of macrophage-borne TGF-β during collagen production ( Figure 4G ). Altogether, these data suggest that in the present disease model, MaR1 and RvD2 locally act on macrophages, dampening the local inflammatory phenotype and favoring a proresolving milieu. This, in turn, acts on the surrounding smooth muscle cells and induces the production of collagen that stabilizes the atherosclerotic plaque.
Discussion
Atheroprogression has long been regarded as a chronic inflammation; however, recent concepts also view atherosclerosis as a consequence of failed resolution. 3, 28 Resolution is crucially orchestrated by a switch from inflammatory to resolving lipid mediators in the affected tissue, 29 an event that is possibly impaired during atheroprogression. 21 Here, we show that as atherosclerosis progresses inflammatory lipid mediators overwhelm their resolving counterparts. In the current disease model, increased levels of LTB4 and PGE2 directly correlate with plaque vulnerability, whereas RvD2 and MaR1 are associated with plaque stability. With the decline of RvD2 and MaR1 during atheroprogression, we chose to repetitively administer these lipid mediators as experimental therapeutic strategy. This setup allowed to halt atheroprogression as observed by reduced necrotic core sizes, thicker fibrous caps, and expansion of smooth muscle cells accompanied by the reduction of macrophage accumulation. Central to this were changes in the macrophage profile from an inflammatory toward a reparative phenotype secondarily stimulating atheroprotective effects in smooth muscle cells (Online Figure IX) .
In contrast to acute inflammatory situations, atheroprogression is characterized by the persistence of the initiating stimulus, including hypertension, hyperlipidemia, and oxidative stress. 3, 28 Interestingly, the synthesis of LTB4, driven by 5-lipoxygenase, depends on reactive oxygen species and is inhibited by nitric oxide, 30 a milieu typically prevailing in progressing atherosclerotic lesions. In addition, the local cytokine environment favors the accumulation of inflammatory over reparative macrophages.
31
LTB4 and PGE2 are produced in abundance at sites of inflammation, [32] [33] [34] suggesting their production by inflammatory macrophages. In accordance, metabololipidomic studies on human monocyte-derived macrophages show that M1 macrophages contain higher levels of LTB4 and PGE2, and, importantly, favor the synthesis of inflammatory lipid mediators, in comparison to their M2 counterpart. 35 Thus, and albeit proresolving lipid mediators are being temporarily synthesized throughout the course of chronic inflammation, the arterial inflammatory milieu during atheroprogression crucially shapes the imbalance of arterial lipid mediators. Such an observation is also herein grounded by the prevailing M1 macrophage phenotype found in the atherosclerotic plaque of vehicle-treated mice, in comparison to the M2 phenotype found in MaR1/RvD2-treated group and the content of reparative macrophages found within the lesion at early stages of the disease (mice subjected to HFD feeding for 4 weeks). Mechanistically, LTB4 potentiates atherosclerosis by increasing the expression of fatty acid translocase/CD36 and of CCL2 (chemokine (C-C motif) ligand 2) hereby inducing a positive feed-back loop to recruit leukocytes. 36, 37 PGE2, as well as PGD2, on the other hand has been reported to have a dual, and paradoxical, role, functioning as proinflammatory and proresolving mediator, depending on its location. 38 In the context of atherosclerosis, PGE2 is associated with disease progression, mediated by the activation of platelets 33 and consequently monocyte recruitment. 39 In general, lipid mediators are mostly produced by myeloid cells, where often the same cell can be the source of both classes of lipid mediators. Under inflammatory conditions, neutrophils 40, 41 and macrophages 35, 42 preferentially synthesize LTB4 and PGE2 over MaR1 and RvD2. Also endothelial 43 and epithelial cells 44 add to the pool of LTB4 and PGE2 production. On a switch toward resolution, macrophages (reparative) and neutrophils (possibly second wave neutrophils) also synthesize MaR1 8 and RvD2. 35, 45 However, during the course of a chronic inflammation, such as atherosclerosis, it is likely that overall the inflammatory environment prevails, favoring the synthesis of inflammatory lipid mediators.
The observed imbalance of arterial lipid mediators raised the question whether the administration of the decreased resolving mediators (MaR1 and RvD2) prompts inhibition of atheroprogression, thus possibly disclosing a novel therapeutic concept in the context of atherosclerosis. Although MaR1 and RvD2 share leukocyte-related functions, few observations point out in the direction of distinct roles for these proresolving lipid mediators. 9 Hence, we have administered a combination of MaR1 and RvD2 as a therapeutic approach in our disease model. Indeed, mice receiving resolving lipid mediators exhibited lesions with stability traits comparable to the baseline group, with additional improved smooth muscle cells numbers, collagen content, fibrous cap thickness, and increased numbers of reparative macrophages. In line with previous reports, 5, 6, 8 our in vitro studies confirmed that RvD2 and MaR1 have the ability to skew macrophage phenotype toward resolution-like, with increased TGF-β production and secretion. In accordance, and much like the lesion phenotype observed in this study, macrophage-borne TGF-β gives rise to lesions characterized by smooth muscle cell accumulation, collagen deposition, and lower macrophage numbers. 46 In vitro, MaR1 and RvD2 reduced the secretion of proinflammatory cytokines by macrophages, an effect that was earlier reported for RvD2. 17 Hence, overall, the actions of MaR1 and RvD2 on macrophages fully support a dampening of the inflammatory milieu within the lesion. Resolving lipid mediators are mostly found in self-resolving exudates, suggesting their synthesis by M2 macrophages. 5, 16 In agreement, M2 macrophages produce more proresolving lipid mediators than M1. 35 These observations then suggest a positive feedback loop, by the administration of MaR1 and RvD2, that further feeds resolution of inflammation and halts atheroprogression. Indeed, positive loops of resolution have been previously reported, 47 such as the stimulation of synthesis of Lipoxin A4 by Resolvin E1. 48 MaR1-and RvD2-treated mice exhibited lesions with increased levels of collagen, when compared with vehicle-treated group. Collagen within the atherosclerotic plaque mainly originates from smooth muscle cells. Despite MaR1 and RvD2 being able to directly exert effects on smooth muscle cells, 23 in this study, the increased collagen levels observed within the lipid mediator treated-group were explained by direct actions of MaR1 and RvD2 on the macrophages, which in turn, by changing the surrounding milieu, stimulated collagen production by smooth muscle cells.
Despite the success of lipid-lowering statins, antiplatelet or antihypertensive compounds, mortality from cardiovascular disease remains high, and the development of specific plaque stabilization therapies is a major challenge in preventive cardiology. The current inflammation-focused understanding of atherosclerotic plaque destabilization has led to the emergence of numerous preclinical developments. However, recent examples of obstacles in the clinical phase epitomize the pitfalls inherent to cardiovascular drug development. For example, neutralization of TNF, a signature cytokine released from activated macrophages, does not reduce the risk of acute coronary syndrome. There are many such examples available, 4 showing that recent strategies targeting inflammation in the context of plaque destabilization are full of intrinsic obstacles and alternative approaches are required. In addition, anti-inflammatory therapies mostly antagonize specific pathways engaged on inflammation, and in spite several ongoing clinical trials and their beneficial effects at early stages of inflammation, anti-inflammatory approaches can be immunosuppressive and limit repair. 29, 49, 50 The transfer of concepts of resolution from bench to bedside requires a shift from inhibitory therapy to replacement therapy, that is, from antagonism to agonism. While anti-inflammatory actions are limited to an inhibitory response, proresolution involves stimulation and initiation of processes, such as apoptosis, efferocytosis, changes in macrophage phenotype and repair. Moreover, proresolution mediators have been associated with positive feedback loops, where one proresolving mediator induces another. 47 On the contrary, anti-inflammatory drugs, such as those inhibiting COX-2 (cyclooxygenase 2), have been reported to delay the resolution of inflammation, by disrupting the production of anti-inflammatory prostaglandins and lipoxins. [51] [52] [53] [54] Thus, our study is in support of the potential translational relevance of resolution-inducing agonists in cardiovascular disease progression. What New Information Does This Article Contribute?
• Inflammatory lipid mediators Leukotriene B4 and Prostaglandin E2 directly correlate with traits of plaque vulnerability, whereas resolving lipid mediators Resolvin D2 (RvD2) and Maresin 1 (MaR1) directly correlate with plaque stability.
• In an atheroprogression mouse model, RvD2 and MaR1 induce plaque stability by favoring a reparative macrophage phenotype accompanied by a decrease of lesional macrophage accumulation and an increase in smooth muscle cells. • RvD2 and MaR1 shift the profile of lesional macrophages from inflammatory to reparative, favoring a proresolution milieu, with increased transforming growth factor-β levels and decreased tumor necrosis factor and interleukin-6 (IL-6).
• RvD2-and MaR1-treated macrophages instruct smooth muscle cells to produce collagen. • The administration of RvD2 and MaR1 prevents atheroprogression suggesting these mediators as potential therapeutic candidates to avert plaque destabilization.
As a chronic inflammation, atherosclerosis also exhibits signs of failed resolution, a process that is determined by a switch in the lipid mediator class. Resolving lipid mediators, the derivatives from docosahexaenoic and eicosapentaenoic fatty acids, actively orchestrate the resolution of inflammation. Clinical and animal model studies attribute protective features to docosahexaenoic and eicosapentaenoic fatty acids in atheroprogression, which positively correlate with decreased inflammation and increased plaque stability. However, the actions of docosahexaenoic and eicosapentaenoic in atherosclerosis are poorly understood. This study evidences, in a murine atheroprogression model, an imbalance between inflammatory and resolving lipid mediators that hinders the resolution of inflammation. Inflammatory Leukotriene B4 and Prostaglandin E2 directly associate with increased macrophage accumulation, decreased collagen deposition and smooth muscle cell number, all traits of plaque instability. On the contrary, administration of resolving mediators MaR1 and RvD2 in a murine model of atheroprogression results in increased lesional plaque stability. Atherosclerotic plaques of treated mice presented decreased macrophage accumulation, increased numbers of smooth muscle cells, and collagen deposition. Moreover, in these lesions, the macrophage phenotype was primarily reparative. In vitro studies show that MaR1 and RvD2 induce a proresolving phenotype in macrophages that then secrete less tumor necrosis factor and IL-6 while increasing the transforming growth factor-β release. Interestingly, the macrophage secretome, in turn, acts on smooth muscle cells, stimulating collagen production. Taken together, our data suggest that treatment with MaR1 and RvD2 halts atheroprogression and promotes lesion stability. 
